Establishment and Preclinical Therapy of Patient-derived Hepatocellular Carcinoma Xenograft Model
Establishment and Preclinical Therapy of Patient-derived Hepatocellular Carcinoma Xenograft Model
复制标题
人源性肝细胞癌异种移植模型的建立及临床前治疗
DOI：
10.1016/j.imlet.2020.04.009
复制
发表时间：
2020-07-01
影响因子：
4.4
通讯作者：
Sun, Cheng
中科院分区：
文献类型：
--
作者：
Wu, Yuwei;Wang, Jinyu;Sun, Cheng
Hepatocellular carcinoma (HCC) is a world-wide health problem. Poor and delayed diagnoses as well as high recurrence rate resulting in high mortality rate. In this study, we established a patient-derived xenograft (PDX) model from HCC patient, and continuously maintained with subcutaneous passage more than 20 times. This HCC PDX tumor exhibited the same histological characteristics with the HCC patient and could be used to verify therapeutic effect of liver cancer. We further evaluated this PDX model by experimental chemotherapy, demonstrating that this HCC PDX model was sensitive to sorafenib treatment. Further, the potential of natural killer cell-based immunotherapy for HCC was tested using this model. We found that NK92 cells effectively suppressed the tumor growth in vivo and prolonged the survival time of HCC-bearing PDX mice. This study indicates that HCC PDX model is a good platform to testify the efficacy of preclinical chemotherapy and immunotherapy.
